Biogen and Ionis flying high as Spinraza meets endpoint

7 November 2016
2019_biotech_test_vial_discovery_big

US biotech firm Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) have announced that Spinraza (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), has met the primary endpoint of a Phase III trial.

Cherish, the study evaluating Spinraza in later-onset SMA, found that children receiving the drug experienced a highly statistically-significant improvement in motor function compared to those who did not receive treatment. It also demonstrated a favorable safety profile in the trial.

Biogen was trading nearly 7% higher at $296.24 after two hours of trading on Monday, while California-based RNA-targeted drug discovery and development company Ionis, was up 19% at $32.28.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology